Management of Patients with Nonmetastatic Castration-Resistant Prostate Cancer: Recommendations of a Multidisciplinary Panel of Experts from South America

<table class="table-group" id="tab1"><tr><td><table class="table"><tr><td class="thead-hr" colspan="3"><hr/></td></tr><tr class="thead"><td class="align_left"> </td><td class="align_center">Sensitivity (95% CI)</td><td class="align_center">Specificity (95% CI)</td></tr><tr><td class="thead-hr" colspan="3"><hr/></td></tr><tr><td class="align_left">PET<sup>11</sup>C-choline</td><td class="align_center">85% (79–89)</td><td class="align_center">88% (73–95)</td></tr><tr><td class="align_left">PET<sup>18</sup>F-fluciclovine</td><td class="align_center">87% (80–92)</td><td class="align_center">66% (56–75)</td></tr><tr><td class="align_left" colspan="3"><hr/></td></tr><tr><td class="align_left">PET<sup>68</sup>Ga-PMSA PET/CT</td><td class="align_center">86% (37–98)</td><td class="align_center">86% (3–100)</td></tr><tr class="table-tr"><td colspan="3"><hr class="tbody-hr"/></td></tr></table></td></tr><tr class="table-fn"><td><div>CI, confidence interval; PET, positron emission tomography; PMSA, prostate-specific membrane antigen. Adapted from Gupta et al. [<a href="/journals/pc/2021/3334333/#B4" target="_blank">4</a>].<br/></div></td></tr></table>

<div>Diagnostic performance of novel imaging techniques.</div>

Prostate Cancer

tab1

Table 1

Table 1: Management of Patients with Nonmetastatic Castration-Resistant Prostate Cancer: Recommendations of a Multidisciplinary Panel of Experts from South America 

Table 1 | Management of Patients with Nonmetastatic Castration-Resistant Prostate Cancer: Recommendations of a Multidisciplinary Panel of Experts from South America 